Mass Tort brief
Lead Counsel in 3M Foam Deal, Bayer Roundup Verdict, and Expanding Mass Torts
Federal judges push mega-settlements forward while appellate rulings and bellwether schedules test corporate liability boundaries.
Mass Tort
Mass Tort
Bayer secured a crucial post-SCOTUS courtroom victory — winning the first trial under new federal preemption rules strengthens its hand as it settles remaining claims for $7.25B.
BackgroundBayer acquired Monsanto in 2018, inheriting tens of thousands of lawsuits alleging glyphosate exposure caused non-Hodgkin lymphoma. The Supreme Court recently ruled that federal pesticide labeling laws preempt state-level failure-to-warn claims, forcing plaintiffs to pursue alternative negligence theories.
- Plaintiffs attempted to bypass federal preemption by litigating theories of design defect and fraud, but the jury rejected all counts in Bayer's favor.
- A City of St. Louis circuit court judge is conducting final fairness hearings on a $7.25 billion settlement fund structured across 21 years.
- U.S. District Judge Vince Chhabria received party briefs examining whether remaining federal multidistrict litigation claims survive Supreme Court preemption standards.
Mass Tort
The 3M firefighting foam deal is entering its distribution phase — appointing lead counsel locks in a $7.35B settlement covering 120,000 personal injury cancer claims.
BackgroundAqueous film-forming foam contains synthetic per- and polyfluoroalkyl substances (PFAS) that persist in groundwater and human tissue, earning the name 'forever chemicals'. Claimants in the South Carolina multidistrict litigation allege prolonged exposure caused kidney, testicular, and liver cancers.
- Judge Gergel established a hard deadline of November 13, 2026, for eligible cancer claimants to formally register under Case Management Order 39, setting the stage for initial payout calculations.
- Hoyle succeeds the late mass tort pioneer Joe Rice, taking direct operational control of claimant distributions while continuing litigation against remaining chemical makers like DuPont and Chemours.
- The agreement resolves personal injury claims while leaving phase three municipal property and environmental remediation suits on a separate trial track, ensuring further financial exposure for secondary manufacturers.
Mass Tort
Medical device litigation is testing blood clot risks — Bard faces its first bellwether over catheter-induced blood clots after a $40M fracture verdict raised settlement pressure.
BackgroundPort catheter devices are surgically implanted under the skin to deliver long-term chemotherapy and intravenous medications directly into large veins. Lawsuits allege that polyurethane and silicone catheter components crack, migrate, or promote vascular blood clots that cause strokes and heart damage.
- Senior U.S. District Judge David G. Campbell scheduled the Hicks trial to establish valuation benchmarks for vascular blood clot injuries.
- The upcoming trial follows a $40 million compensatory jury verdict awarded to a plaintiff whose fractured catheter migrated directly into her heart.
- Becton Dickinson is appealing earlier trial losses while preparing defense arguments on catheter biocompatibility and surgeon warning instructions.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
